ReviewJournal of Alzheimer's disease : JAD2010
Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease.
Review in Journal of Alzheimer's disease : JAD, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns.Molecular neurodegeneration · 2021Pooled it
- Intervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer's Symptomatic Expression (INCREASE) Study: Results from a Randomized Controlled Study of Medication Therapy Management Targeting a Delay in Prodromal Dementia Symptom Progression.The journal of prevention of Alzheimer's disease · 2022Trial
- Novel Plasma Proteins Associated With Alzheimer's Disease Risk in APOE ε4 Carriers and Non-carriers.Research square · 2026Article
- Frontal Release Signs and Future Decline in Research Participants With Intact Cognition.JAMA network open · 2026Article
- Bayesian multivariate longitudinal piecewise regression: detecting early onset of cognitive decline.Journal of behavioral medicine · 2026Article
- A New Perspective on Agitation in Alzheimer's Disease: A Potential Paradigm Shift.International journal of molecular sciences · 2025Article
- Neuropsychiatric symptoms and neuroimaging-based brain age in mild cognitive impairment and early dementia: A multicenter study.Psychiatry and clinical neurosciences · 2025Article
- Exploring the Efficacy and Target Genes ofCurrent issues in molecular biology · 2025Article
- Trends of the Dementia Burden in South Asia: An Analysis of 2021 Global Burden of Disease Study.Aging medicine (Milton (N.S.W)) · 2025Article
- From pixels to prognosis: radiomics and AI in Alzheimer's disease management.Frontiers in neurology · 2025Review
- Cutting-edge Strategies for Overcoming Therapeutic Barriers in Alzheimer's Disease.Current pharmaceutical design · 2025Review
- Effects of amyloid-β-mimicking peptide hydrogel matrix on neuronal progenitor cell phenotype.Acta biomaterialia · 2024Article
- The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment.International journal of molecular sciences · 2023Article
- Neuropsychiatric symptoms associated multimodal brain networks in Alzheimer's disease.Human brain mapping · 2023Article
- Low Serum Vitamin D Status Is Associated with Incident Alzheimer's Dementia in the Oldest Old.Nutrients · 2022Article
- The Transcranial Light Therapy Improves Synaptic Plasticity in the Alzheimer's Disease Mouse Model.Brain sciences · 2022Article
- Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.The Lancet. Public health · 2022Article
- Cannabidiol Inhibits Tau Aggregation In Vitro.Cells · 2021Article
- Endophenotypical drift in Huntington's disease: a 5-year follow-up study.Orphanet journal of rare diseases · 2021Article
- Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.Brain sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Over the past several decades, our understanding of Alzheimer's disease (AD) has seen an evolution from the dichotomous concept of normal versus AD in the dementia state to a more accurate and complete appreciation of AD as a progressive disorder with clinical, biological, and pathological features occurring along a continuum from normal to end-stage disease. Integrating our understanding of the relationships and interplay between the clinical, biological, and pathological features of AD may allow the identification of AD at even preclinical, completely asymptomatic stages of the disease. This review attempts to summarize the clinical stages of AD in terms of epidemiology, historical evolution of disease stage diagnoses, cognitive/neuropsychologic features, psychiatric/behavioral manifestations, and functional decline in the context of our developing understanding of the biological processes responsible for the pathogenesis of AD described in detail in the accompanying articles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.